5-Amino-1MQ 50mg

5-Amino-1MQ 50mg

NNMT Inhibitor · Preclinical NAD+ Rescue · Research Only

What is it and how does it work?

5-Amino-1-Methylquinolinium (5-Amino-1MQ) is a small molecule (non-peptide) — a selective, cell-permeable inhibitor of the NNMT enzyme (Nicotinamide N-Methyltransferase). The preclinical literature documents that NNMT blockade slows SAM and nicotinamide consumption, raising intracellular NAD+ and reactivating the salvage pathway, with effects in animal models on SIRT1 activity, lipolysis, lipogenesis suppression, and reactivation of senescent muscle stem cells.

Primary preclinical evidence documented in rodents: Neelakantan H et al. (2018) Biochem Pharmacol 154:161-171 (PMID 29183836) — foundational study in high-fat-diet mice (DIO), 20 mg/kg SubQ TID × 11 days → body weight reduction and white adipose mass loss without change in intake. Neelakantan H et al. (2019) Biochem Pharmacol 163:481-492 (PMID 30753815) — aged-muscle mouse model, NNMTi reactivated senescent muscle stem cells with +~70% peak torque in tibialis anterior. Research material only — no FDA-approved human use.

Reconstitution

• Vial 50 mg lyophilized
• Bacteriostatic water: 2 ml (tablet — standard rule would be 10 ml, doesn't fit in 3ml vial)
• Resulting concentration: 25,000 mcg/ml
• Per unit U-100: 250 mcg · verification: 25,000 ÷ 100 = 250 mcg/u ✓
• Conservation Refrigerate 2–8°C · Use within 28–30 days after reconstituting
• Performance Equivalent volume: 200 U-100 units per reconstituted vial

Documented evidence in research literature

Combinations reported in literature

• 5-Amino-1MQ + MOTS-C in preclinical literature: independent mitochondrial pathways — NNMTi rescues NAD+, MOTS-C activates AMPK and mitochondrial biogenesis. No mechanistic overlap.
• 5-Amino-1MQ + Tesamorelin/CJC-Ipa: independent axes in research — GH/IGF-1 vs metabolic modulation via NAD+/SIRT1.
• 5-Amino-1MQ + AOD 9604: lipólisis directa (AOD) + bloqueo de lipogénesis y rescate energético (NNMTi) en modelos animales.
• 5-Amino-1MQ + injectable NAD+: the literature reports complementarity — NNMTi stops the leak via nicotinamide methylation; injectable NAD+ replenishes substrate.
• 5-Amino-1MQ + Retatrutide in emerging literature: triple GLP/GIP/GCG agonism + NAD+/SIRT1 metabolic modulation in body-composition research.

Practical notes

• Small molecule — NOT a peptide. Stable quinolinium with high membrane permeability. 50 mg vial compressed to 2 ml due to the physical limit of the 3 ml vial — concentration 25,000 mcg/ml.
• Primary preclinical literature used SubQ administration in mice (Neelakantan 2018, 2019). Commercial guides typically cite oral administration for volume practicality in small mammals.

Contraindications and precautions

• Research material only. No FDA-approved human use. All evidence is preclinical (mouse). No established long-term human safety data. Not for human use.

Research material only. No FDA-approved human use. This product is intended for scientific research purposes in controlled laboratory settings only. It is not a drug. Not for human or animal administration, therapeutic use, or diagnostic use.